Barclays
ANIK icon

Barclays’s Anika Therapeutics ANIK Stock Holding History

Barclays’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-120,000
Closed -$2.76M – 7512
2013
Q3 		$2.76M Buy
+120,000
New +$2.69M ﹤0.01% 2226

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Barclays's ANIK Position: Q1 2026 in Review

Barclays reduced its Anika Therapeutics (ANIK) stake by 25% in Q1 2026, selling an estimated $204K and leaving 52,928 shares worth $767K. The position accounts for ﹤0.01% of the portfolio, ranked #2916.

Barclays first reported a position in ANIK in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.93M in Q3 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Barclays held 52,928 shares of Anika Therapeutics worth $767K as of Q1 2026.
  • Barclays sold 17,578 Anika Therapeutics shares in Q1 2026, an estimated $204K.
  • Anika Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2916 holding.
  • Barclays first reported a position in Anika Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Anika Therapeutics position peaked at $1.93M in Q3 2019.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.